Agfa-Gevaert NV (AGE.F)
| Previous Close | 2.5800 |
| Open | 2.6050 |
| Bid | 2.6350 x 250000 |
| Ask | 2.6600 x 250000 |
| Day's Range | 2.6050 - 2.6150 |
| 52 Week Range | 2.4400 - 4.1450 |
| Volume | |
| Avg. Volume | 295 |
| Market Cap | 404.857M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | 0.72 |
| EPS (TTM) | 3.6540 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Agfa to invest in new industrial unit for Zirfon membranes for green hydrogen production
Agfa to invest in new industrial unit for Zirfon membranes for green hydrogen production Mortsel, Belgium – March 8, 2023 – 7.45 a.m. CET Agfa today announced that, given the strong increase in demand, the Board of Directors validated the investment for a new industrial unit for the company’s Zirfon membranes for green hydrogen production, next to further investments in growing the current facility. The unit will be installed in existing buildings at the company’s site in Mortsel, Belgium. When
- GlobeNewswire
The Agfa-Gevaert Group in full year 2022 - regulated information
Regulated information – March 8, 2023 - 7:45 a.m. CET The Agfa-Gevaert Group in full year 2022: Adjusted EBITDA decrease of 9% versus 2021 due to continuing cost inflation, lockdowns in China and softer demand in non-healthcare marketsHealthCare IT: momentum created Significant improvement in order intake, both in terms of volume and in terms of quality, resulting in top line growth and stabilization of recurring revenueConversion of sales growth in EBITDA delayed by post-COVID reinvestments in
- GlobeNewswire
Agfa-Gevaert Group Q3 Results 2022 - Regulated information – November 9, 2022 - 7:45 a.m. CET
The Agfa-Gevaert Group in Q3 2022: Adjusted EBITDA increase of 8% with contrasted performances between the divisions HealthCare IT: organic sales growth, strong increase in order intake, solid profitabilityDigital Print & Chemicals: contrasted top line performance between the various activities – demand weakness and cost inflation impact – strong sales for Digital Print and Zirfon membranesRadiology Solutions: medical film business impacted by lockdowns in China and margin pressureOffset Solutio
